Agenus (NASDAQ: AGEN) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Agenus to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.
Volatility & Risk
Agenus has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Agenus’ peers have a beta of 1.58, suggesting that their average stock price is 58% more volatile than the S&P 500.
37.9% of Agenus shares are held by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.6% of Agenus shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Agenus and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus currently has a consensus price target of $6.33, suggesting a potential upside of 78.91%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.27%. Given Agenus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Agenus is more favorable than its peers.
This table compares Agenus and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Agenus and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agenus||$22.57 million||-$126.99 million||-3.03|
|Agenus Competitors||$217.29 million||-$39.39 million||-70.32|
Agenus’ peers have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Agenus peers beat Agenus on 7 of the 13 factors compared.
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
What are top analysts saying about Agenus? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agenus and related companies.